Acupuncture versus sham acupuncture and usual care for Antiandrogen-Induced hot fLashes in prostate cancer (AVAIL): study protocol for a randomized clinical trial

BMC Complement Med Ther. 2023 Oct 27;23(1):388. doi: 10.1186/s12906-023-04218-y.

Abstract

Background: Hot flashes are the common and debilitating symptom among prostate cancer (PCa) patients undergoing androgen deprivation therapy (ADT). Strong evidence from multiple rigorously designed studies indicated that pharmacological option such as venlafaxine provides partial relief, but the tolerability is poor when dose is not tapered. Hence, alternative therapy is needed. Previous studies reported that acupuncture may be helpful in the management of hot flashes. However, the insufficient randomized controlled trial limited the quality of evidence.

Methods: Five hospitals will recruit 120 acupuncture naïve patients with moderate-to-severe hot flashes after prostate cancer received ADT in China from February 2023 to December 2024. Participants will be randomly 2:1:1 allocated to the 18 sessions of verum acupuncture at true acupuncture points plus usual care, 18 sessions of non-penetrating sham acupuncture at non-acupuncture points plus usual care, or usual care alone over 6 weeks. The primary outcome measure is the change of mean weekly hot flashes symptom severity score (HFSSS) at the end of treatment compared with baseline.

Expected results and conclusion: We will be able to measure the effectiveness of acupuncture for patients with PCa suffering from ADT-induced hot flashes and whether acupuncture is superior to sham acupuncture and usual care. The proposed acupuncture treatment might provide an alternative option for those patients.

Trial registration: Clinicaltrials.gov (NCT05069467).

Keywords: Acupuncture; Hot flashes; Prostate cancer; Quality of life; Randomized controlled trial; Sham acupuncture; Study protocol.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Acupuncture Points
  • Acupuncture Therapy* / methods
  • Androgen Antagonists / adverse effects
  • Hot Flashes / etiology
  • Hot Flashes / therapy
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Androgen Antagonists

Associated data

  • ClinicalTrials.gov/NCT05069467